Gastroenteropancreatic neuroendocrine tumor — GI origin (carcinoid), well-differentiated G1/G2 · line 1 · Lanreotide Autogel 120 mg SC q4w (well-differentiated GEP-NET G1/G2; CLARINET)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-LANREOTIDE-AUTOGEL-GI-NET |
| ID | IND-GI-NET-ADVANCED-1L-LANREOTIDE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-03 | pending_clinical_signoff |
| Diseases | DIS-GI-NET |
| Sources | SRC-CLARINET-CAPLIN-2014 SRC-NCCN-NET-2025 |
Notes
STUB — requires clinical co-lead signoff (CHARTER §6.1 dev-mode exemption). PRRT (¹⁷⁷Lu-DOTATATE; NETTER-1 trial, Strosberg NEJM 2017) is the major 2L option after SSA progression for SSTR2+ GI-NET. NETTER-1 showed ORR 18% and mPFS not reached vs 8.4 mo (HR 0.21). PRRT requires DOTATATE PET eligibility and specialized centre. Deferred for separate KB SSTR biomarker scaffolding + drug entity (DRUG-LUTETIUM-177-DOTATATE).
Used By
Algorithms
ALGO-GI-NET-ADVANCED-1L- ALGO-GI-NET-ADVANCED-1L